{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:11:24Z","timestamp":1765357884794,"version":"3.44.0"},"reference-count":24,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,9,2]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n<jats:title>Objectives and design<\/jats:title>\n<jats:p>To further elucidate the effects of rare systemic autoimmune rheumatic diseases (SARD) and their treatment on antibody development after vaccination against SARS-CoV-2, we compared patients with and without immunosuppressive therapy to healthy controls in an observational cohort study.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Participants and setting<\/jats:title>\n<jats:p>We enrolled 52 patients with SARD and 72 healthy subjects in a prospective, observational study at the Medical University of Vienna and measured the humoral response 6\u2009months after two mRNA vaccinations and 2\u20136 weeks after a third dose.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n    <jats:p>Patients with vasculitis showed significantly (p=0.02) lower antibody titres 6\u2009months after vaccination (median 247 BAU\/mL, IQR [185\u2013437]), as compared with healthy controls (median 514 BAU\/mL, [185\u2013437], IQR 323; 928, vasculitis patients: 247, IQR [185; 437], p&lt;0.05). Patients receiving 2\u20133 immunomodulatory medications showed significantly lower antibody levels. Of note, all patients with SARD, even those without immunomodulatory medication, developed lower antibody levels after the third dose compared with healthy controls (median 22 630, IQR [16 945; 43\u2009200] in HC, 9510 IQR [3866; 14\u2009215] in patients without immunosuppressive treatment (p&lt;0.001), 7780 IQR [2203; 15\u2009645] in patients receiving a single immunomodulatory drug (p&lt;0.0001) and 14\u2009320 IQR [2415; 35\u2009400] in patients receiving combination therapy (p=0.081)).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Patients with SARD displayed lower antibody development after booster vaccination, even if antibody levels after two immunisations were comparable to healthy controls. Our data may be limited due to sample size, but it provides pointers for a more individualised, antibody-titre-oriented approach and earlier booster vaccination in patients with SARD.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bmjopen-2024-094948","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T15:43:07Z","timestamp":1758728587000},"page":"e094948","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody development after three mRNA SARS-CoV-2 vaccinations in patients with systemic autoimmune rheumatic disease with and without treatment: an observational cohort study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8177-9949","authenticated-orcid":false,"given":"Elisabeth","family":"Simader","sequence":"first","affiliation":[{"name":"Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Kartnig","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma","family":"Tobudic","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Wien, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Mrak","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Deimel","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Karonitsch","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-2503","authenticated-orcid":false,"given":"Helmuth","family":"Haslacher","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, Wien, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Perkmann","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, Wien, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Mitter","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Winkler","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Wien, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Blueml","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mandl","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"2025092320000646000_15.9.e094948.1","doi-asserted-by":"crossref","DOI":"10.1007\/s11940-020-00646-0","article-title":"Secondary Causes of Myositis","volume":"22","author":"Berth","year":"2020","journal-title":"Curr Treat Options Neurol"},{"key":"2025092320000646000_15.9.e094948.2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05301-2"},{"key":"2025092320000646000_15.9.e094948.3","doi-asserted-by":"crossref","first-page":"e778","DOI":"10.1016\/S2665-9913(21)00222-8","article-title":"Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies","volume":"3","author":"Boekel","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025092320000646000_15.9.e094948.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.269"},{"key":"2025092320000646000_15.9.e094948.5","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2665-9913(21)00212-5","article-title":"The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study","volume":"3","author":"Mahil","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025092320000646000_15.9.e094948.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220781"},{"key":"2025092320000646000_15.9.e094948.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221347"},{"key":"2025092320000646000_15.9.e094948.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220461"},{"key":"2025092320000646000_15.9.e094948.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221788"},{"key":"2025092320000646000_15.9.e094948.10","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1049157","article-title":"The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination","volume":"10","author":"Tobudic","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2025092320000646000_15.9.e094948.11","first-page":"964","article-title":"Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic","volume":"10","author":"Sahebari","year":"2022","journal-title":"Arch Bone Jt Surg"},{"key":"2025092320000646000_15.9.e094948.12","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00272-2"},{"key":"2025092320000646000_15.9.e094948.13","doi-asserted-by":"publisher","DOI":"10.1089\/bio.2018.0032"},{"key":"2025092320000646000_15.9.e094948.14","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.03149-20","article-title":"Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation","volume":"59","author":"Higgins","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2025092320000646000_15.9.e094948.15","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaa198"},{"key":"2025092320000646000_15.9.e094948.16","doi-asserted-by":"crossref","first-page":"906457","DOI":"10.3389\/fimmu.2022.906457","article-title":"Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"2025092320000646000_15.9.e094948.17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1296273","article-title":"Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study","volume":"15","author":"Kared","year":"2024","journal-title":"Front Immunol"},{"key":"2025092320000646000_15.9.e094948.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222579"},{"key":"2025092320000646000_15.9.e094948.19","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1136\/annrheumdis-2021-222006","article-title":"EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update","volume":"81","author":"Landew\u00e9","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025092320000646000_15.9.e094948.20","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1007\/s10067-022-06348-z","article-title":"Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients","volume":"41","author":"Pri-Paz Basson","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2025092320000646000_15.9.e094948.21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002293","article-title":"Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination","volume":"8","author":"Andreica","year":"2022","journal-title":"RMD Open"},{"key":"2025092320000646000_15.9.e094948.22","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1007\/s10238-023-01163-5","article-title":"Impact of methotrexate on humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis","volume":"23","author":"Shirata","year":"2023","journal-title":"Clin Exp Med"},{"key":"2025092320000646000_15.9.e094948.23","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.medcli.2023.12.011","article-title":"Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases","volume":"162","author":"Romero-Bogado","year":"2024","journal-title":"Med Clin (Barc)"},{"key":"2025092320000646000_15.9.e094948.24","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001435","article-title":"Evaluation of the effects of pre-exposure treatment with hydroxychloroquine on the risk of COVID-19 infection and on the efficacy of anti-COVID-19 vaccination during lupus or Gougerot-Sj\u00f6gren\u2019s disease: Prepcov multicentre trial","volume":"12","author":"Alric","year":"2025","journal-title":"Lupus Sci Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-094948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T15:43:09Z","timestamp":1758728589000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-094948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,23]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bmjopen-2024-094948"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-094948","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}